Akt1 rs2498801 is related to survival in head and neck squamous cell cancer treated with radiotherapy

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 269-272

  Pasqualetti, Francesco ^a   Bocci, Guido ^b   Mey, Valentina ^b   Menghini, Valentina ^a   Montrone, Sabrina ^a   Cocuzza, Paola ^a   Ferrazza, Patrizia ^a   Seccia, Veronica ^a   Delishaj, Durim ^a   Orlandini, Cinzia ^a   Fabrini, Maria Grazia ^a   Danesi, Romano ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

AKT; Chemotherapy; Head neck; Radiotherapy

Indexed keywords

CETUXIMAB; CISPLATIN; CONTRAST MEDIUM; DOCETAXEL; FLUOROURACIL; AKT1 PROTEIN, HUMAN; PROTEIN KINASE B;

AKT1 GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOMOZYGOSITY; HOSPITAL PATIENT; HUMAN; MALE; OVERALL SURVIVAL; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; CARCINOMA, SQUAMOUS CELL; GENETICS; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MORTALITY; PROPORTIONAL HAZARDS MODEL;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE;

EID: 84920439037     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006.
3. Toker A and Cantley LC: Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387: 673-676, 1997.
4. Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, Lobrich M and Rodemann HP: Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNAPKcs- dependent DNA double-strand break repair. Mol Cancer Ther 7: 1772-1781, 2008.
5. Golding SE, Morgan RN, Adams BR, Hawkins AJ, Povirk LF and Valerie K: Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biol Ther 8: 730-738, 2009.
6. Pfisterer K, Fusi A, Klinghammer K, Knodler M, Nonnenmacher A and Keilholz U: PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Head Neck 2014.
7. Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB and Shu YQ: Genetic variants in the PI3K/PTEN/ AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population. Asian Pac J Cancer Prev 13: 2157-2162, 2012.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
9. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Irigoyen A, Sastre J, Martinez-Trufero J, Brandariz Castelo JA, Verger E and Cruz-Hernandez JJ: A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25: 216-225, 2014.
10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
11. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS and Muschel RJ: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892, 2002.
12. Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN and Papadimitrakopoulou VA: Akt activation correlates with adverse outcome in tongue cancer. Cancer 104: 2430-2436, 2005.